• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hologic Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    4/6/26 8:00:56 AM ET
    $HOLX
    Medical Electronics
    Health Care
    Get the next $HOLX alert in real time by email
    false0000859737DE00008597372026-04-062026-04-06

    graphic
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM 8-K


    Current Report Pursuant
    to Section 13 or 15(d) of the
    Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported) April 6, 2026


    HOLOGIC, INC.
    (Exact Name of Registrant as Specified in Its Charter)



    DELAWARE
    (State or Other Jurisdiction of Incorporation)

    001-36214
     
    04-2902449
    (Commission File Number)
     
    (I.R.S. Employer Identification No.)

    250 Campus Drive, Marlborough, Massachusetts
     
    01752
    (Address of Principal Executive Offices)
     
    (Zip Code)

    (508) 263-2900
    (Registrant’s Telephone Number, Including Area Code)

    (Former Name or Former Address, if Changed Since Last Report)


    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act.

    Title of each class
    Trading Symbol(s)
    Name of each exchange on which registered
    Common Stock, $.01 par value
    HOLX
    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
     
    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



    Item 5.02
    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

    On April 6, 2026, Stephen P. MacMillan informed the Board of Directors of Hologic, Inc. (the “Company”) of his retirement as President and Chief Executive Officer and as Chairman of the Board of Directors of the Company, contingent upon, and effective as of immediately after, the closing of the acquisition of the Company by affiliates of funds managed by Blackstone Inc. and TPG Global, LLC pursuant to the Agreement and Plan of Merger, dated October 21, 2025, by and among the Company, Hopper Parent Inc. and Hopper Merger Sub Inc (the “Merger”).

    A copy of the Company’s press release announcing Mr. MacMillan’s retirement is filed with this Current Report on Form 8-K as Exhibit 99.1.

    Item 8.01
    Other Events.

    On April 6, 2026, the Company announced it has received all regulatory approvals necessary to complete the Merger.  The transaction is expected to close on or about April 7, 2026, subject to the satisfaction or waiver of customary closing conditions.
     
    Cautionary Statement Regarding Forward-Looking Statements
     
    This Current Report on Form 8-K includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “intends,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “likely,” “future,” “strategy,” “potential,” “seeks,” “goal” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the benefits of and timeline for closing the merger. These forward-looking statements are based upon assumptions made by Hologic as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those anticipated.
     

    These forward-looking statements are subject to a number of risks and uncertainties that could adversely affect Hologic’s business and prospects, and otherwise cause actual results to differ materially from those anticipated, including without limitation, the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement entered into in connection with the proposed transaction; the risk that the parties to the merger agreement may not be able to satisfy the conditions to the proposed transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the proposed transaction; the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of Hologic’s common stock; the risk of any unexpected costs or expenses resulting from the proposed transaction; the risk of any litigation relating to the proposed transaction; the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Hologic to retain and hire key personnel and to maintain relationships with customers, vendors, partners, employees, stockholders and other business relationships and on its operating results and business generally; and the risk that the holders of the CVRs will receive less-than-anticipated payments with respect to the CVRs after the closing of the proposed transaction. Further information on factors that could cause actual results to differ materially from the results anticipated by the forward-looking statements is included in the Hologic Annual Report on Form 10-K for the fiscal year ended September 27, 2025 filed with the Securities and Exchange Commission (the “SEC”) on November 18, 2025, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings made by Hologic from time to time with the SEC. These filings, when available, are available on the investor relations section of the Hologic website at https://investors.hologic.com or on the SEC’s website at https://www.sec.gov. If any of these risks materialize or any of these assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Hologic presently does not know of or that Hologic currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. The forward-looking statements included in this Current Report on Form 8-K are made only as of the date hereof. Hologic expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statements presented herein to reflect any change in expectations or any change in events, conditions or circumstances on which any such statements are based, except as required by law.
     
    Item 9.01
    Financial Statements and Exhibits

    (d) Exhibits

    Exhibit
    Number
     
    Description
    99.1
     
    Press Release dated April 6, 2026.
    104
     
    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

    Date: April 6, 2026
    HOLOGIC, INC.
     
           
     
    By:
    /s/ Anne M. Liddy
     
       
    Anne M. Liddy
     
       
    General Counsel
     



    Get the next $HOLX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HOLX

    DatePrice TargetRatingAnalyst
    1/12/2026Buy → Hold
    Argus
    1/5/2026$78.00Outperform → In-line
    Evercore ISI
    11/21/2025$79.00Outperform → Neutral
    BNP Paribas Exane
    10/7/2025$78.00In-line → Outperform
    Evercore ISI
    8/18/2025$80.00Hold → Buy
    Argus
    8/6/2025$87.00Sector Perform → Outperform
    RBC Capital Mkts
    7/9/2025$80.00Neutral → Buy
    Citigroup
    5/27/2025Hold
    Needham
    More analyst ratings

    $HOLX
    SEC Filings

    View All

    Hologic Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - HOLOGIC INC (0000859737) (Filer)

    4/6/26 8:00:56 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hologic Inc.

    SCHEDULE 13G/A - HOLOGIC INC (0000859737) (Subject)

    3/27/26 9:33:26 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form 8-K filed by Hologic Inc.

    8-K - HOLOGIC INC (0000859737) (Filer)

    2/6/26 8:00:17 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Hologic downgraded by Argus

    Argus downgraded Hologic from Buy to Hold

    1/12/26 9:02:06 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Hologic from Outperform to In-line and set a new price target of $78.00

    1/5/26 8:48:38 AM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic downgraded by BNP Paribas Exane with a new price target

    BNP Paribas Exane downgraded Hologic from Outperform to Neutral and set a new price target of $79.00

    11/21/25 8:06:35 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

    NEW YORK, April 6, 2026 /PRNewswire/ -- S&P MidCap 400 constituent Casey's General Stores Inc. (NASD: CASY) will replace Hologic Inc. (NASD: HOLX) in the S&P 500, S&P SmallCap 600 constituent DigitalOcean Holdings Inc. (NYSE:DOCN) will replace Casey's General Stores in the S&P MidCap 400, and Broadstone Net Lease Inc. (NYSE:BNL) will replace DigitalOcean Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 9. Affiliates of Blackstone Inc. and TPG Global are acquiring Hologic in a deal expected to be completed on or about April 7. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Dat

    4/6/26 5:51:00 PM ET
    $BNL
    $CASY
    $DOCN
    Real Estate Investment Trusts
    Real Estate
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Hologic Chief Executive Officer Steve MacMillan to Retire Upon Close of Go-Private Transaction

    Hologic, Inc. (NASDAQ:HOLX) announced today that Steve MacMillan, its long-time Chairman, President and Chief Executive Officer (CEO), has decided to retire when the Company's go-private transaction with Blackstone and TPG closes. All required regulatory approvals have now been received for the transaction, which is expected to close on or about April 7, 2026. "Hologic's board of directors, and all the Company's stakeholders, owe a debt of gratitude to Steve, one of the most respected leaders in the medical technology industry," said Amy Wendell, Hologic's lead independent director. "He forged a dramatic turnaround shortly after joining the Company, led us through years of consistent gr

    4/6/26 8:00:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    1.5 Billion Women Miss Essential Preventive Tests, Despite Uptick in Global Screening Rates

    Fifth edition of Hologic Global Women's Health Index reveals over half of women worldwide weren't tested for key conditions in the past year Hologic and Gallup convene experts to discuss closing gaps in screening access Global women's health leader Hologic, Inc. (NASDAQ:HOLX) today released data showing that while testing for some health conditions has risen among women globally, a vast screening gap remains. Over half of women and girls aged 15 and older — an estimated 1.5 billion women — were not tested for cancer, high blood pressure, diabetes or sexually transmitted infections (STIs) in the past year. This press release features multimedia. View the full release here: https://www.b

    3/17/26 8:00:00 AM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 29, 2024 - FDA Roundup: October 29, 2024

    For Immediate Release: October 29, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA responded to objections on the agency’s final rule that removed the authorized food contact uses of most phthalates because industry abandoned these uses. The FDA evaluated the objections and concluded that they did not provide a basis for mod

    10/29/24 3:30:19 PM ET
    $HOLX
    Medical Electronics
    Health Care

    February 2, 2024 - FDA Roundup: February 2, 2024

    For Immediate Release: February 02, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a safety communication to warn consumers, health care providers, and health care facilities not to use certain Cardinal Health Monoject luer-lock and enteral syringes. Dimensional changes made to the syringes, when used with syringe pump

    2/2/24 3:58:21 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Liddy Anne M. covered exercise/tax liability with 185 shares, decreasing direct ownership by 0.66% to 28,052 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:30:37 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Wendell Amy Mcbride was granted 3,190 shares, increasing direct ownership by 14% to 25,784 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:29:04 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Director Stewart Stacey D. was granted 3,190 shares, increasing direct ownership by 62% to 8,358 units (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    3/2/26 4:27:37 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Madaus Martin D bought $300,760 worth of shares (5,445 units at $55.24) (SEC Form 4)

    4 - HOLOGIC INC (0000859737) (Issuer)

    5/9/25 4:39:33 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Financials

    Live finance-specific insights

    View All

    Hologic Announces Financial Results for First Quarter of Fiscal 2026

    – Revenue of $1,047.8 Million Grows 2.5% – – GAAP Diluted EPS of $0.79 Decreases (9.2%), Non-GAAP Diluted EPS of $1.04 Up 1.0% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal first quarter ended December 27, 2025. The Company reported revenue of $1,047.8 million, GAAP diluted EPS of $0.79, and non-GAAP diluted EPS of $1.04. Highlights The Company has scheduled for February 5, 2026 a special meeting of stockholders to vote on adopting the merger agreement with funds managed by Blackstone and TPG, and related matters. Revenue of $1,047.8 million increased 2.5% for the quarter, or 1.3% on a constant currency basis. Total organic reve

    1/29/26 4:02:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic to Announce Financial Results for the First Quarter of Fiscal 2026 on Thursday, January 29, 2026

    Hologic, Inc. (NASDAQ:HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2026 on Thursday, January 29, after the market closes. As previously announced, in light of Hologic's pending acquisition by Blackstone and TPG, the Company will not be hosting a quarterly conference call or providing financial guidance. About Hologic Hologic, Inc. is an innovative medical technology company primarily focused on improving women's health and well-being through early detection and treatment. For more information on Hologic, visit www.hologic.com. SOURCE: Hologic, Inc. View source version on businesswire.com: https://www.businesswire.com/

    1/15/26 7:00:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    Hologic Announces Financial Results for Fourth Quarter of Fiscal 2025

    – Revenue of $1,049.5 Million Grows 6.2% – – GAAP Diluted EPS of $0.83 Increases 9.2%, Non-GAAP Diluted EPS of $1.13 Up 11.9% – Hologic, Inc. (NASDAQ:HOLX) announced today the Company's financial results for the fiscal fourth quarter ended September 27, 2025. The Company reported revenue of $1,049.5 million, GAAP diluted EPS of $0.83, and non-GAAP diluted EPS of $1.13. Highlights On October 21, 2025, the Company announced it had entered into a definitive agreement to be acquired by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share (the "Proposed Transaction"). Revenue of $1,049.5 million increased 6.2% for the quarter, or 5.4% in constant currenc

    11/3/25 4:01:00 PM ET
    $HOLX
    Medical Electronics
    Health Care

    $HOLX
    Leadership Updates

    Live Leadership Updates

    View All

    Casey's General Stores Set to Join S&P 500; DigitalOcean Holdings to Join S&P MidCap 400; Broadstone Net Lease to Join S&P SmallCap 600

    NEW YORK, April 6, 2026 /PRNewswire/ -- S&P MidCap 400 constituent Casey's General Stores Inc. (NASD: CASY) will replace Hologic Inc. (NASD: HOLX) in the S&P 500, S&P SmallCap 600 constituent DigitalOcean Holdings Inc. (NYSE:DOCN) will replace Casey's General Stores in the S&P MidCap 400, and Broadstone Net Lease Inc. (NYSE:BNL) will replace DigitalOcean Holdings in the S&P SmallCap 600 effective prior to the opening of trading on Thursday, April 9. Affiliates of Blackstone Inc. and TPG Global are acquiring Hologic in a deal expected to be completed on or about April 7. Following is a summary of the changes that will take place prior to the open of trading on the effective date:Effective Dat

    4/6/26 5:51:00 PM ET
    $BNL
    $CASY
    $DOCN
    Real Estate Investment Trusts
    Real Estate
    Retail-Auto Dealers and Gas Stations
    Consumer Discretionary

    Biote Announces CEO Retirement and Succession Plan

    Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

    1/30/25 4:10:00 PM ET
    $BTMD
    $HOLX
    $MYGN
    Medicinal Chemicals and Botanical Products
    Health Care
    Medical Electronics
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    CellMax Life Announces Expansion of Company Board With Leading Industry Experts

    Renowned industry experts join to aid in preparation around premarket approval for FirstSight SUNNYVALE, Calif., April 6, 2023 /PRNewswire-PRWeb/ -- CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced the appointment of Stanley N. Lapidus (Stan) as an advisory board member and Ronnie (Ron) Andrews as an independent board member. The announcement comes only one month after CellMax Life expanded its GI advisory board with luminaries in the GI arena. "Both Stan and Ron are pioneers in the diagnostics industry, with unique perspectives and proven track records of success," said Atul Sharan, CEO of CellMax Life. Stan is one of t

    4/6/23 9:00:00 AM ET
    $EXAS
    $HOLX
    Medical Specialities
    Health Care
    Medical Electronics

    $HOLX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Hologic Inc.

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    11/14/24 1:28:29 PM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G filed by Hologic Inc.

    SC 13G - HOLOGIC INC (0000859737) (Subject)

    2/14/24 10:04:34 AM ET
    $HOLX
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by Hologic Inc. (Amendment)

    SC 13G/A - HOLOGIC INC (0000859737) (Subject)

    2/9/23 11:22:19 AM ET
    $HOLX
    Medical Electronics
    Health Care